醋酸卡貝縮宮素
| 中文名稱 | 醋酸卡貝縮宮素 |
|---|---|
| 中文同義詞 | 醋酸卡貝縮宮素 37025-55-1;卡貝縮宮素三氟醋酸鹽;卡比托辛/卡貝縮宮素;醋酸卡貝縮宮素,卡比托辛;卡貝縮宮素;醋酸卡貝縮宮素;卡比托辛;卡貝縮官素;卡貝縮宮素 |
| 英文名稱 | Carbetocin |
| 英文同義詞 | Butyryl-Tyr(Me)-Ile-Gln-Asn-Cys-Pro-Leu-Gly-NH2(Disulfide bond);N-(4-Mercapto-1-oxobutyl)-O-methyl-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-L-prolyl-L-leucyl-glycinamidecyclic (1-5)-thioether acetate;CARBAOXYTOCIN;Carbetocin, (Butyryl1,Tyr(Me)2)-1-Carbaoxytocin;BUTYRYL-TYR(ME)-ILE-GLN-ASN-CYS-PRO-LEU-GLY-NH2, (SULFIDE BOND BETWEEN BUTYRYL-4-YL AND CYS);BUTYRYL-TYR(ME)-ILE-GLN-ASN-CYS-PRO-LEU-GLY-NH2 TRIFLUOROACETATE SALT;(BUTYRYL1,TYR(ME)2)-1-CARBAOXYTOCIN TRIFLUOROACETATE SALT;(BUTYRYL1,TYR(ME)2)-OXYTOCIN |
| CAS號(hào) | 37025-55-1 |
| 分子式 | C45H69N11O12S |
| 分子量 | 988.17 |
| EINECS號(hào) | 253-312-6 |
| 相關(guān)類別 | 原料藥（API）;多肽;醫(yī)藥原料藥;醫(yī)用原料;多肽原料藥;生物制藥;原料藥;Peptide;Vasopressin and Oxytocin receptor;Intermediates & Fine Chemicals;Pharmaceuticals;Other APIs;醫(yī)藥原料藥 科研原料;醫(yī)藥原料;藥物多肽;雜質(zhì)對(duì)照品;肽類;標(biāo)準(zhǔn)品;生物化工;化學(xué)產(chǎn)品 |
| Mol文件 | 37025-55-1.mol |
| 結(jié)構(gòu)式 |  |
醋酸卡貝縮宮素 性質(zhì)
| 熔點(diǎn) | 140 - 160°C |
|---|---|
| 沸點(diǎn) | 1477.9±65.0 °C(Predicted) |
| 比旋光度 | D -69.0° (c = 0.25 in 1M acetic acid) |
| 密度 | 1.218±0.06 g/cm3(Predicted) |
| 儲(chǔ)存條件 | -15°C |
| 溶解度 | 可溶于DMSO（少許）、甲醇（少許） |
| 形態(tài) | 粉末 |
| 酸度系數(shù)(pKa) | 13.07±0.70(Predicted) |
| 顏色 | 白色至米色 |
| 水溶解性 | Soluble to 29.65 mg/ml in water |
| 穩(wěn)定性 | 吸濕性 |
| InChIKey | NSTRIRCPWQHTIA-FOILTOEQNA-N |
Carbetocin is an agonist with about 10-fold lower affinity for the oxytocin receptor but with significantly higher stability and a longer duration of action. Carbetocin has higher affinity to the chimeric E1 receptor and especially to each of the combinations of E1 with the other extracellular domains, i.e. chimeric receptors E13 (K
i
=13 nM), E123 (K
i
=56 nM), and E1234 (K
i
=37 nM).
Carbetocin (2-20 mg/kg; i.p.) has a significant effect of treatment on the percent time spent climbing, swimming and immobile.
Carbetocin (1, 10,100 μg/rat, i.c.v.) reveals a dose-dependent increase in the percent time spent swimming and a corresponding reduction in immobility following acute administration of 100 μg/rat.
| Animal Model: | Male Sprague-Dawley rats weighing between 300 and 500 g |
| Dosage: | 2, 6.4, 20 mg/kg |
| Administration: | IP; single dose |
| Result: | Increased climbing with 6.4 mg/kg and resulted in a significantly greater proportion of time spent swimming with 20 mg/kg. |
安全信息
| WGK Germany | 3 |
|---|
| 更新日期 | 產(chǎn)品編號(hào) | 產(chǎn)品名稱 | CAS號(hào) | 包裝 | 價(jià)格 |
|---|---|---|---|---|---|
| 2025/05/22 | HY-17573A | 醋酸卡貝縮宮素 Carbetocin acetate | 37025-55-1 | 1 mg | 200元 |
| 2025/05/22 | HY-17573A | 醋酸卡貝縮宮素 Carbetocin acetate | 37025-55-1 | 5mg | 500元 |